Quinidine is a very potent inhibitor of CYP2D6, but the role of the enzyme in the biotransformation of quinidine has only been investigated in a single in vitro study and in two small in vivo experiments, with contradictory results. The present investigation was designed to present definite evaluation of whether quinidine is metabolised by CYP2D6. Eight poor metabolizers (PM) and 8 extensive metabolizers (EM) of sparteine each took one oral dose of 200 mg quinidine. In the EM, the total clearance, the clearance via 3-hydroxylation and the clearance via N-oxidation, were 33, 3.7 and 0.23 l·h−1, respectively. In the PM, the corresponding values were 29, 3.1 and 0.18 l·h−1, respectively. There were no statistically significant differences between EM and PM in any of these pharmacokinetic parameters. It is concluded that CYP2D6 is not an important enzyme for the oxidation of quinidine.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by beta-adrenoreceptor antagonists and other cardiovascular agents. Life Sci 34:73–80
Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W (1985) A human cytochrome P450 characterized by inhibition studies of the sparteine-debrisoquine monooxygenase. Canad J Physiol Pharmacol 62:860–862
Brinn R, Brøsen K, Gram LF, Haghfelt T, Otton SV (1986) Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 22:194–197
Brøsen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60:312–314
Otton SV, Brinn RU, Gram LF (1988) In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos 16:15–17
Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M (1986) Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 31:69–72
Brøsen K, Davidsen F, Gram LF (1990) Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 29:248–253
Smith E, Barhan S, Ross B, Maienthal M, Levine J (1973) Examination of quinidine and quinine and their pharmaceutical preparations. J Pharm Sci 62:1151–1155
Brøsen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57:357–360
Nielsen F, Nielsen KK, Brøsen K (1994) Determination of quinidine, dihydroquinidine, (3S)-3OH-quinidine and quinidine-N-oxide in plasma and urine, by high-performance liquid chromatography. J Chromatogr 660:103–110
Drayer DE, Lowenthal DT, Restivo K, Schwartz KM, Cook CE, Reidenberg MM (1978) Steady state serum levels of quinidine and active quinidine metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther 24:31–39
Leroyer R, Varoquaux O, Advenier C, Pays M (1990) Quinidine oxidative metabolism. Identification and biosynthesis of quinidine-10, 11-dihydrdiol stereoisomers. Biomed Chromatogr 4:61–64
Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kaludbar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modelling. Cancer Res 45:2116–2122
Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T (1986) The molecular mechanisms of two common polymorphisms of drug oxidation — evidence for functional changes in cytochrome P-450 isozymes catalyzing bufaralol and mephenytoin oxidation. Xenobiotica 16:449–464
Koymans L, Vermeulen NPE, vanAcker ABE, teKoppele JM, Keykants JP, Lavrijsen K, Meuldermans W, Donné-Op den Kelder GM (1992) A predictive Model for Substrates of Cytochrome P450-Debrisoquine (2D6). Chem Res Toxicol 5: 211–219
Dohorty R, Benson WR, Maienthal M, Stewart JMcD (1978) Crystal and Molecular Structure of Quinidine. J Pharm Sci 67:1698–1701
Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol: 287–290
Spinler SA, Cheng JWM, Kindwall KE, Charland SL (1995) Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 57:89–94
About this article
Cite this article
Nielsen, F., Rosholm, J.U. & Brøsen, K. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 48, 501–504 (1995). https://doi.org/10.1007/BF00194341
- Sparteine oxidation polymorphism